• +41 91 682 20 40
  • info@elixi-int.com
  • Reserved Area
    • Login
    • Register
    • Request Document
    • Send Document
logo
  • Home
  • About Us
  • Services
  • Quality
  • News
  • Case Studies
  • Contact

Let's talk

info@yourwebsite.com
+1 (555) 123-4567

  • Search

Elixi

7 June 2021

Wegovy (semaglutide) injection – first approved drug for chronic weight management since 2014


0 Comments5 Minutes

1 June 2021

Lumakras (sotorasib), first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C


0 Comments3 Minutes

3 May 2021

Farxiga (dapagliflozin) Approved for the treatment of Chronic Kidney Disease


0 Comments4 Minutes

27 April 2021

Enspryng (satralizumab), new treatment for rare autoimmune disease of nerve cells


0 Comments2 Minutes

17 April 2021

Novartis receives EU approval for Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis


0 Comments3 Minutes

3 April 2021

Abecma (idecabtagene vicleucel), First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma


0 Comments2 Minutes

23 March 2021

ARCALYST (rilonacept) is the first FDA-approved therapy for recurrent pericarditis


0 Comments3 Minutes

27 February 2021

Evrysdi (Risdiplam), First oral treatment for spinal muscular atrophy (SMA)


0 Comments3 Minutes

14 February 2021

Cosela (trilaciclib), first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression


0 Comments1 Minutes

9 February 2021

Breyanzi (lisocabtagene maraleucel), new Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma


0 Comments2 Minutes

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 13

Warning:

A cybersecurity incident is under investigation. Please be carefull with emails or phone calls that correctly mention your name, role, or current transactions. Elixi’s crisis team is working to limit any harmful impact, as the security of our clients’ and suppliers’ data is Elixi’s top priority. For any clarification, you can contact: DPO@elixi-int.com

Si è verificato un evento di sicurezza informatica in corso di analisi. Vi invitiamo a prestare massima attenzione messaggi di posta elettronica o telefonate che citano correttamente il vostro nome, la funzione o operazioni realmente avvenute. Il crisis team di Elixi sta lavorando per limitare ogni conseguenza dannosa, perchè la sicurezza dei dati dei nostri clienti e dei fornitori è la nostra priorità di Elixi. Per ogni chiarimento potete contattare: DPO@elixi-int.com